Status:
COMPLETED
Standard or Convalescent Plasma in Patients With Recent Onset of COVID-19 Respiratory Failure
Lead Sponsor:
A.O.U. Città della Salute e della Scienza
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To date no specific treatment has been proven to be effective for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) infection. It is possible that convalescent plasma that contains antibodi...
Detailed Description
500-700 ml of Plasma will be collected by apheresis from COVID recovered donors showing the presence of neutralizing antibodies to SARS-Cov-2 (anti-SARS-Cov-2). All plasma will be screened for transmi...
Eligibility Criteria
Inclusion
- Confirmed SARS-Cov-2 diagnosis by RT-PCR on nasopharyngeal swab or on bronchoalveolar lavage
- Respiratory failure onset or progression within 5 days
- Signed Informed Consent
Exclusion
- Pregnancy
- Previous severe reactions to plasma transfusion
- Unavailability of blood group compatible COVID-19 convalescent plasma
Key Trial Info
Start Date :
June 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 31 2021
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT04428021
Start Date
June 15 2020
End Date
October 31 2021
Last Update
February 23 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
AO Città della salute e della scienza di Torino
Torino, Italy, 10126